Edition:
United States

Amyris Inc (AMRS.O)

AMRS.O on Nasdaq

4.09USD
21 Jul 2017
Change (% chg)

$-0.04 (-0.97%)
Prev Close
$4.13
Open
$4.15
Day's High
$4.20
Day's Low
$3.93
Volume
227,467
Avg. Vol
244,660
52-wk High
$18.15
52-wk Low
$2.63

AMRS.O

Chart for AMRS.O

About

Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including... (more)

Overall

Beta: 0.10
Market Cap(Mil.): $81.80
Shares Outstanding(Mil.): 19.81
Dividend: --
Yield (%): --

Financials

  AMRS.O Industry Sector
P/E (TTM): -- 17.66 38.07
EPS (TTM): -6.71 -- --
ROI: -71,925.30 7.27 11.10
ROE: -- 9.94 14.24

BRIEF-Amyris enters into first product development, production agreement with Royal DSM

* Amyris enters into first product development and production agreement with Royal DSM for food and nutrition molecule

Jul 17 2017

BRIEF-Amyris, on June 30, 2017, company issued, sold an amended, restated note in principal amount of $3 mln to purchaser

* Amyris Inc - on June 30, 2017, company issued and sold an amended and restated note in principal amount of $3.0 million to purchaser - sec filing

Jul 07 2017

BRIEF-Amyris and government of Queensland announced plans to develop a industrial biotechnology hub in Southeast Asia

* Amyris Inc and government of Queensland, Australia announced plans to develop a industrial biotechnology hub in Southeast Asia Source text for Eikon: Further company coverage:

Jun 20 2017

BRIEF-Amyris announces reverse stock split

* Amyris announces reverse stock split - delivering on strong product revenue growth and execution

Jun 06 2017

BRIEF-Amyris reports Q1 loss per share of $0.13

* Amyris reports 164 pct product revenue growth over prior year & continued strong outlook

May 15 2017

BRIEF-Amyris on-track to double revenue for vitamin e partnership

* Amyris on-track to double revenue for vitamin e partnership with nenter & announces exclusive vitamin a license with royal DSM

May 10 2017

BRIEF-Royal DSM to make equity investment in Amyris

* Royal DSM to make equity investment in amyris with the purpose of establishing a long-term relationship Source text for Eikon: Further company coverage:

May 08 2017

BRIEF-Royal DSM to make equity investment in Amyris

* Royal DSM to make equity investment in Amyris with the purpose of establishing a long-term relationship Source text for Eikon: Further company coverage:

May 08 2017

BRIEF-Amyris announces agreements for up to $95 mln in equity financing

* Amyris announces agreements for up to $95 million in equity financing and in-process initiative to significantly reduce debt

May 08 2017

BRIEF-Amyris makes develomental progress in its healthy sweetener product technology

* Amyris Inc - made significant progress in development of its healthy sweetener product technology and expects industrial production to occur in 2018

May 01 2017

Earnings vs. Estimates